Robert F. Apple is CEO & President at ANTARES PHARMA, INC. (ATRS). They have made 9 open-market trades across 1 company since 2012, most recently 2022-05-24.
CIK 0001054942
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $43K since 2016, against 8 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ATRS | SELL | 2021-02-17 | 2021-02-19 | $5.00 | $2.6M | -10.5% | -10.9% | -14.5% |
| ATRS | SELL | 2021-02-08 | 2021-02-10 | $4.75 | $820K | -5.3% | -3.2% | -17.5% |
| ATRS | SELL | 2019-12-10 | 2019-12-11 | $4.76 | $279K | +0.4% | -6.3% | -34.5% |
| ATRS | SELL | 2019-12-09 | 2019-12-11 | $4.63 | $1.4M | +0.4% | -6.3% | -34.5% |
| ATRS | SELL | 2019-12-09 | 2019-12-11 | $4.66 | $2.0M | +0.4% | -6.3% | -34.5% |
| ATRS | SELL | 2018-08-21 | 2018-08-23 | $3.75 | $161K | -2.8% | -8.1% | -7.5% |
| ATRS | SELL | 2017-04-04 | 2017-04-05 | $3.00 | $120K | -8.7% | +0.3% | +4.7% |
| ATRS | SELL | 2017-04-04 | 2017-04-05 | $3.00 | $111K | -8.7% | +0.3% | +4.7% |
| ATRS | BUY | 2016-03-18 | 2016-03-18 | $0.72 | $43K | +16.0% | +18.7% | +38.7% |
| ATRS | SELL · 10b5-1 | 2014-01-10 | 2014-01-14 | $5.00 | $50K | -22.0% | -2.5% | -2.5% |
| ATRS | SELL · 10b5-1 | 2013-10-14 | 2013-10-16 | $5.05 | $111K | -22.0% | -2.5% | -2.5% |
| ATRS | SELL · 10b5-1 | 2013-06-03 | 2013-06-05 | $4.01 | $462K | -22.0% | -2.5% | -2.5% |
| ATRS | SELL · 10b5-1 | 2013-05-06 | 2013-05-08 | $4.02 | $40K | -22.0% | -2.5% | -2.5% |
| ATRS | SELL · 10b5-1 | 2013-01-08 | 2013-01-10 | $4.01 | $100K | -22.0% | -2.5% | -2.5% |
| ATRS | SELL · 10b5-1 | 2012-12-04 | 2012-12-06 | $4.00 | $100K | -22.0% | -2.5% | -2.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.